JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

NVS

120.31

+2.04%↑

Search

Eli Lilly and Co.

Geschlossen

BrancheGesundheitswesen

795.48 0.43

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

785.34

Max

798.46

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.1B

2.8B

Verkäufe

-804M

13B

KGV

Branchendurchschnitt

62.756

50.291

EPS

3.34

Dividendenrendite

0.79

Gewinnspanne

21.678

Angestellte

47,000

EBITDA

-2B

4.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+26.16% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.79%

2.40%

Nächstes Ergebnis

6. Aug. 2025

Nächste Dividendenausschüttung

10. Sept. 2025

Nächstes Ex-Dividendendatum

15. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-136B

692B

Vorheriger Eröffnungskurs

795.05

Vorheriger Schlusskurs

795.48

Nachrichtenstimmung

By Acuity

38%

62%

125 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juni 2025, 11:56 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27. Mai 2025, 14:41 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17. Juni 2025, 14:02 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17. Juni 2025, 12:12 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17. Juni 2025, 11:01 UTC

Akquisitionen, Fusionen, Übernahmen

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17. Juni 2025, 10:47 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17. Juni 2025, 10:47 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17. Juni 2025, 10:46 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17. Juni 2025, 10:45 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17. Juni 2025, 09:33 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11. Juni 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29. Mai 2025, 01:00 UTC

Top News

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28. Mai 2025, 18:09 UTC

Ergebnisse

Heart Disease Could Be a Goner When These New -2-

28. Mai 2025, 18:09 UTC

Ergebnisse

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27. Mai 2025, 14:02 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27. Mai 2025, 14:01 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27. Mai 2025, 14:00 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27. Mai 2025, 14:00 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20. Mai 2025, 14:08 UTC

Ergebnisse

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. Mai 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. Mai 2025, 11:18 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6. Mai 2025, 20:30 UTC

Top News

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4. Mai 2025, 04:05 UTC

Akquisitionen, Fusionen, Übernahmen

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1. Mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1. Mai 2025, 14:07 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Peer-Vergleich

Kursveränderung

Eli Lilly and Co. Prognose

Kursziel

By TipRanks

26.16% Vorteil

12-Monats-Prognose

Durchschnitt 999.57 USD  26.16%

Hoch 1,190 USD

Tief 700 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eli Lilly and Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

16

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 884.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

125 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.